Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients
Salem Anaesthesia Pain Clinic
150 participants
Nov 8, 2022
OBSERVATIONAL
Conditions
Summary
Prospective observational crossover study of 150 consenting adult patients who are undergoing chronic pain management. For insomnia treatment, each patient ingests prescribed doses of Lemborexant or Zopiclone or Clonidine on alternate nights. Each patient uses a special validated sleep diary to collect data including pain score, sleep score, sleep duration, sleep medication type, and adverse effects. Each patient completes the diary for 3 continuous weeks. Pain is measured using the numeric pain rating scale. Sleep score is measured using the Likert sleep scale. A change in the pain or sleep scores by 2-points is considered significant.
Eligibility
Inclusion Criteria9
- adult chronic pain patients
- good treatment compliance
- severe chronic insomnia
- failure of non-pharmacologic sleep therapy
- regular zopiclone therapy for 3 months or more
- regular sleep diary
- regular pain diary
- informed consent for diary review
- consent for clinical record quality assurance review
Exclusion Criteria19
- obstructive sleep apnoea
- body mass index (BMI) ≥40
- organ insufficiency
- cognitive disorder
- inability to provide consent
- major neuropsychiatric disorder
- unreliable diary
- cannabis use
- regular alcohol intake
- stimulant use
- substance abuse
- poor treatment compliance
- high dose opioid
- gabapentinoid use
- sedative use
- mild insomina
- irregular zopiclone intake
- regular zopiclone therapy for less than 3 months
- previous adverse/allergic reactions to clonidine or zopiclone
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
For insomnia treatment, each patient ingests Lemborexant or Zopiclone or Clonidine on alternate nights. Each patient uses a special validated sleep diary to collect data.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05618002